1
|
Abolarinwa BA, Shaw MK, Lee CH. Perspectives on Challenges to Cell Therapy Development in Taiwan: Strengthening Evidential Standards and Ways Forward. Front Bioeng Biotechnol 2021; 9:789043. [PMID: 34976978 PMCID: PMC8716849 DOI: 10.3389/fbioe.2021.789043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2021] [Accepted: 11/29/2021] [Indexed: 11/13/2022] Open
Abstract
Over the past years, the field of regenerative medicine and cell therapy has garnered much interest, extending beyond the bench to broader use, and commercialization. These therapies undergo stringent regulatory oversight as a result of their complexities and potential risk across different jurisdictions. Taiwan’s government, with the aim of developing the country as a hub for regenerative medicine in Asia, enacted a dual track act to promote the development of regenerative and cell therapy products. This qualitative study used purposive sampling to recruit sixteen experts (Twelve respondents from medical institutions and four respondents from the industry) to understand their perspectives on one of the regulatory tracks which governs the medical use of cell technologies and challenges regarding its implementation. Semi-structured interviews were conducted, transcribed, coded and thematically analyzed. Three major themes emerged from the analysis: 1) Perceptions of the “Special Regulation for Cell Therapy” 2) Emerging issues and controversies on the medical use of cell technologies in private clinics, and 3) Challenges impeding the clinical innovation of cell technologies. As reported by the experts, it was clear that the special regulation for cell therapy was aimed at legalizing the clinical use of cell therapy in a similar fashion to an evidence-based pathway, to promote clinical innovation, ensure manufacturing consistency, and improve oversight on cell-based therapies. Thus, the regulation addresses the issues of safety concerns, patient’s access and stem cell tourism. However, the limited approved cell techniques, quality control during cell processing, time, and criteria used in evaluating applications in addition to the need to develop evidential standards for clinical evidence are some of the difficulties faced. Thus, policy interventions on funding, educational resources, training, and regulatory clarity addressing these challenges may positively impact clinical innovation of cell therapy in Taiwan.
Collapse
Affiliation(s)
- Bilikis Aderonke Abolarinwa
- International PhD program for Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
| | - Malissa Kay Shaw
- Graduate Institute of Humanities in Medicine, Taipei Medical University, Taipei, Taiwan
- School of Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan
| | - Chung-Hsi Lee
- International PhD program for Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
- Graduate Institute of Health and Biotechnology Law, Taipei Medical University, Taipei, Taiwan
- *Correspondence: Chung-Hsi Lee,
| |
Collapse
|
2
|
Umemura M, Morrison M. Comparative lessons in regenerative medicine readiness: learning from the UK and Japanese experience. Regen Med 2021; 16:269-282. [PMID: 33781099 DOI: 10.2217/rme-2020-0136] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
This paper explores how 'regenerative readiness' varies between different national research and healthcare systems. Here, 'readiness' refers to both the readiness of a given technology and the ability of a given setting to adopt a new technology. We compare two settings that have taken active yet dissonant approaches to improve readiness: the UK and Japan. Existing scholarship observes that disruptive technologies such as regenerative medicine require many adaptations to become useable and function along the principles of their design. We incorporate the sociotechnical systems framework to consider the range of adaptive measures taken across elements of the sociotechnical system for novel technological adoption. Building upon existing works on technology readiness and institutional readiness, we also expand the conceptualization of readiness toward system-wide readiness.
Collapse
Affiliation(s)
- Maki Umemura
- Senior Lecturer in International Business, Cardiff Business School, Cardiff University, Aberconway Building, Colum Drive, Cardiff, CF10 3EU, UK
| | - Michael Morrison
- Senior Researcher in Social Science, Centre for Health, Law & Emerging Technologies, Faculty of Law, University of Oxford, Ewert House, Banbury Road, Oxford, OX2 7DD, UK.,Research Affiliate, Institution for Science Innovation & Society, School of Anthropology & Museum Ethnography, University of Oxford, 51/53 Banbury Road, Oxford, OX2 6PE, UK
| |
Collapse
|
3
|
Leask F, Terzic A. Regenerative outlook: offering global solutions for equitable care. Regen Med 2020; 15:2249-2252. [PMID: 33245010 DOI: 10.2217/rme-2020-0177] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2020] [Accepted: 11/11/2020] [Indexed: 12/18/2022] Open
Affiliation(s)
| | - Andre Terzic
- Department of Cardiovascular Medicine; Department of Molecular Pharmacology & Experimental Therapeutics, Department of Clinical Genomics, Center for Regenerative Medicine, Marriott Heart Disease Research Program, van Cleve Cardiac Regenerative Medicine Program, Mayo Clinic, Rochester, MN 55905, USA
| |
Collapse
|
4
|
Hourd P, Williams DJ. Scanning the horizon for high value-add manufacturing science: Accelerating manufacturing readiness for the next generation of disruptive, high-value curative cell therapeutics. Cytotherapy 2018; 20:759-767. [DOI: 10.1016/j.jcyt.2018.01.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2017] [Revised: 01/08/2018] [Accepted: 01/09/2018] [Indexed: 12/11/2022]
|
5
|
Maartens JH, De-Juan-Pardo E, Wunner FM, Simula A, Voelcker NH, Barry SC, Hutmacher DW. Challenges and opportunities in the manufacture and expansion of cells for therapy. Expert Opin Biol Ther 2017; 17:1221-1233. [DOI: 10.1080/14712598.2017.1360273] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- Joachim H. Maartens
- Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia
- Cooperative Research Centre for Cell Therapy Manufacturing, Adelaide, Australia
| | - Elena De-Juan-Pardo
- Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia
- Cooperative Research Centre for Cell Therapy Manufacturing, Adelaide, Australia
| | - Felix M. Wunner
- Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia
- Cooperative Research Centre for Cell Therapy Manufacturing, Adelaide, Australia
| | - Antonio Simula
- Cooperative Research Centre for Cell Therapy Manufacturing, Adelaide, Australia
| | - Nicolas H. Voelcker
- Cooperative Research Centre for Cell Therapy Manufacturing, Adelaide, Australia
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Future Industries Institute, University of South Australia, Adelaide, Australia
| | - Simon C. Barry
- Cooperative Research Centre for Cell Therapy Manufacturing, Adelaide, Australia
- Molecular Immunology, Department of Gastroenterology, Women’s and Children’s Hospital, Adelaide, Australia
- Robinson Research Institute, University of Adelaide, Adelaide, Australia
| | - Dietmar W. Hutmacher
- Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia
- Cooperative Research Centre for Cell Therapy Manufacturing, Adelaide, Australia
- ARC Centre in Additive Biomanufacturing, Queensland University of Technology, Brisbane, Australia
| |
Collapse
|
6
|
Patra S, Young V. A Review of 3D Printing Techniques and the Future in Biofabrication of Bioprinted Tissue. Cell Biochem Biophys 2016; 74:93-8. [DOI: 10.1007/s12013-016-0730-0] [Citation(s) in RCA: 102] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2015] [Accepted: 04/22/2016] [Indexed: 12/21/2022]
|
7
|
Rafiq QA, Ortega I, Jenkins SI, Wilson SL, Patel AK, Barnes AL, Adams CF, Delcassian D, Smith D. The early career researcher's toolkit: translating tissue engineering, regenerative medicine and cell therapy products. Regen Med 2015; 10:989-1003. [PMID: 26628407 DOI: 10.2217/rme.15.56] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Although the importance of translation for the development of tissue engineering, regenerative medicine and cell-based therapies is widely recognized, the process of translation is less well understood. This is particularly the case among some early career researchers who may not appreciate the intricacies of translational research or make decisions early in development which later hinders effective translation. Based on our own research and experiences as early career researchers involved in tissue engineering and regenerative medicine translation, we discuss common pitfalls associated with translational research, providing practical solutions and important considerations which will aid process and product development. Suggestions range from effective project management, consideration of key manufacturing, clinical and regulatory matters and means of exploiting research for successful commercialization.
Collapse
Affiliation(s)
- Qasim A Rafiq
- Centre for Biological Engineering, Wolfson School of Mechanical & Manufacturing Engineering, Loughborough University, Leicestershire, LE11 3TU, UK.,Aston Medical Research Institute, School of Life & Health Sciences, Aston University, Aston Triangle, Birmingham, B4 7ET, UK
| | - Ilida Ortega
- Bioengineering & Health Technologies Group, The School of Clinical Dentistry, University of Sheffield, S10 2TA, UK
| | - Stuart I Jenkins
- Institute for Science & Technology in Medicine, Keele University, Staffordshire, ST5 5BG, UK
| | - Samantha L Wilson
- Academic Ophthalmology, Division of Clincial Neuroscience, Queen's Medical Centre Campus, University of Nottingham, NG7 2UH, UK
| | - Asha K Patel
- Wolfson Centre for Stem Cells, Tissue Engineering & Modeling, University of Nottingham, Nottingham, NG7 2RD, UK.,David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | | | - Christopher F Adams
- Institute for Science & Technology in Medicine, Keele University, Staffordshire, ST5 5BG, UK
| | - Derfogail Delcassian
- Department of Materials, Imperial College London, Exhibition Road, London SW7 2AZ, UK.,Wolfson Centre for Stem Cells, Centre for Biological Sciences, School of Pharmacy, University of Nottingham, NG7 2RD, UK
| | - David Smith
- Centre for Biological Engineering, Wolfson School of Mechanical & Manufacturing Engineering, Loughborough University, Leicestershire, LE11 3TU, UK.,PCT, a Caladrius company, 4 Pearl Court, Suite C, Allendale, NJ 07401, USA
| |
Collapse
|
8
|
Bulman SE, Coleman CM, Murphy JM, Medcalf N, Ryan AE, Barry F. Pullulan: a new cytoadhesive for cell-mediated cartilage repair. Stem Cell Res Ther 2015; 6:34. [PMID: 25889571 PMCID: PMC4414433 DOI: 10.1186/s13287-015-0011-7] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2014] [Revised: 02/18/2015] [Accepted: 02/18/2015] [Indexed: 01/08/2023] Open
Abstract
Introduction Local delivery of mesenchymal stem cells (MSCs) to the acutely injured or osteoarthritic joint retards cartilage destruction. However, in the absence of assistive materials the efficiency of engraftment of MSCs to either intact or fibrillated cartilage is low and localization is further reduced by natural movement of the joint surfaces. It is hypothesised that enhanced engraftment of the delivered MSCs at the cartilage surface will increase their reparative effect and that the application of a bioadhesive to the degraded cartilage surface will provide improved cell retention. Pullulan is a structurally flexible, non-immunogenic exopolysaccharide with wet-stick adhesive properties and has previously been used for drug delivery via the wet surfaces of the buccal cavity. In this study, the adhesive character of pullulan was exploited to enhance MSC retention on the damaged cartilage surface. Methods MSCs labeled with PKH26 were applied to pullulan-coated osteoarthritic cartilage explants to measure cell retention. Cytocompatability was assessed by measuring the effects of prolonged exposure to the bioadhesive on MSC viability and proliferation. The surface phenotype of the cells was assessed by flow cytometry and their multipotent nature by measuring osteogenic, adipogenic and chrondrogenic differentiation. Experiments were also carried out to determine expression of the C-type lectin Dectin-2 receptor. Results MSCs maintained a stable phenotype following exposure to pullulan in terms of metabolic activity, proliferation, differentiation and surface antigen expression. An increase in osteogenic activity and Dectin-2 receptor expression was seen in MSCs treated with pullulan. Markedly enhanced retention of MSCs was observed in explant culture of osteoarthritic cartilage. Conclusions Pullulan is a biocompatible and effective cytoadhesive material for tissue engraftment of MSCs. Prolonged exposure to pullulan has no negative impact on the phenotype, viability and differentiation potential of the cells. Pullulan dramatically improves the retention of MSCs at the fibrillated surface of osteoarthritic articular cartilage. Pullulan causes an upregulation in expression of the Dectin-2 C-type lectin transmembrane complex.
Collapse
Affiliation(s)
- Sarah E Bulman
- Regenerative Medicine Institute, National University of Ireland Galway, Biosciences, Dangan, Galway, Ireland. .,Smith & Nephew, York Science Park, Heslington, York, YO10 5DF, UK.
| | - Cynthia M Coleman
- Regenerative Medicine Institute, National University of Ireland Galway, Biosciences, Dangan, Galway, Ireland.
| | - J Mary Murphy
- Regenerative Medicine Institute, National University of Ireland Galway, Biosciences, Dangan, Galway, Ireland.
| | - Nicholas Medcalf
- School of Mechanical and Manufacturing Engineering, Loughborough University, Leicestershire, LE11 3TU, UK.
| | - Aideen E Ryan
- Regenerative Medicine Institute, National University of Ireland Galway, Biosciences, Dangan, Galway, Ireland.
| | - Frank Barry
- Regenerative Medicine Institute, National University of Ireland Galway, Biosciences, Dangan, Galway, Ireland.
| |
Collapse
|
9
|
Oerlemans AJM, van Hoek MEC, van Leeuwen E, Dekkers WJM. Hype and expectations in tissue engineering. Regen Med 2014; 9:113-22. [PMID: 24351011 DOI: 10.2217/rme.13.89] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Scientific progress and the development of new technologies often incite enthusiasm, both in scientists and the public at large, and this is especially apparent in discussions of emerging medical technologies, such as tissue engineering (TE). Future-oriented narratives typically discuss potential applications with much hype and expectations. In this article, we analyze the discourse on TE, its history and the promises present in the discourse surrounding it. Subsequently, we regard discussions about implantable bioartificial kidneys, and consider the concepts of hype and expectations in TE in general. Finally, we discuss what ethically responsible choices should be made in discussing TE to adequately deal with the scientific reality and public expectations surrounding this technology.
Collapse
Affiliation(s)
- Anke J M Oerlemans
- Scientific Institute for Quality of Healthcare, Radboud University Medical Center, PO Box 9101 (IQ 114), 6500 HB Nijmegen, The Netherlands
| | | | | | | |
Collapse
|
10
|
Munisi HI, Xie Z, Sengoku S. Exploring innovation in stem cell and regenerative medicine in Japan: the power of the consortium-based approach. Regen Med 2014; 9:467-77. [PMID: 25159064 DOI: 10.2217/rme.14.18] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
This article describes a recent trend in Japanese research, development and commercialization toward the application of stem cell technologies. Japan is the world's third largest economy and has a significant national presence in the pharmaceutical and biotechnology businesses; as such, stem cell R&D is abundant in the country. As indicated by the second largest share of patent applications worldwide, Japan had been expected to assert significant added value in the commercialization and industrial application of stem cell technologies; however, difficulties have impeded clinical development in this area, particularly the very small number of clinical trials and approved products for regenerative medicine or cell therapy. To address this 'Japan paradox', this report provides an overview of approaches for the commercialization of stem cell technologies in areas such as drug discovery, cell therapy and regenerative medicine, by discussing representative case examples of listed firms.
Collapse
Affiliation(s)
- Hawa Issa Munisi
- The Institute for Integrated Cell-Material Sciences (WPI-iCeMS), Kyoto University, Kyoto, Japan
| | | | | |
Collapse
|
11
|
Hutmacher DW. A road map for a tissue engineering concept for restoring structure and function after limb loss. JOURNAL OF MATERIALS SCIENCE. MATERIALS IN MEDICINE 2013; 24:2659-2663. [PMID: 24085493 DOI: 10.1007/s10856-013-5049-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/16/2012] [Accepted: 08/30/2013] [Indexed: 06/02/2023]
Affiliation(s)
- Dietmar W Hutmacher
- Science and Engineering Faculty, Regenerative Medicine Institute of Health and Biomedical Innovation, Queensland University of Technology, 60 Musk Avenue, Kelvin Grove, Brisbane, QLD, 4059, Australia,
| |
Collapse
|
12
|
Henkel J, Woodruff MA, Epari DR, Steck R, Glatt V, Dickinson IC, Choong PFM, Schuetz MA, Hutmacher DW. Bone Regeneration Based on Tissue Engineering Conceptions - A 21st Century Perspective. Bone Res 2013; 1:216-48. [PMID: 26273505 PMCID: PMC4472104 DOI: 10.4248/br201303002] [Citation(s) in RCA: 520] [Impact Index Per Article: 43.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2013] [Accepted: 07/20/2013] [Indexed: 12/18/2022] Open
Abstract
The role of Bone Tissue Engineering in the field of Regenerative Medicine has been the topic of substantial research over the past two decades. Technological advances have improved orthopaedic implants and surgical techniques for bone reconstruction. However, improvements in surgical techniques to reconstruct bone have been limited by the paucity of autologous materials available and donor site morbidity. Recent advances in the development of biomaterials have provided attractive alternatives to bone grafting expanding the surgical options for restoring the form and function of injured bone. Specifically, novel bioactive (second generation) biomaterials have been developed that are characterised by controlled action and reaction to the host tissue environment, whilst exhibiting controlled chemical breakdown and resorption with an ultimate replacement by regenerating tissue. Future generations of biomaterials (third generation) are designed to be not only osteoconductive but also osteoinductive, i.e. to stimulate regeneration of host tissues by combining tissue engineering and in situ tissue regeneration methods with a focus on novel applications. These techniques will lead to novel possibilities for tissue regeneration and repair. At present, tissue engineered constructs that may find future use as bone grafts for complex skeletal defects, whether from post-traumatic, degenerative, neoplastic or congenital/developmental "origin" require osseous reconstruction to ensure structural and functional integrity. Engineering functional bone using combinations of cells, scaffolds and bioactive factors is a promising strategy and a particular feature for future development in the area of hybrid materials which are able to exhibit suitable biomimetic and mechanical properties. This review will discuss the state of the art in this field and what we can expect from future generations of bone regeneration concepts.
Collapse
Affiliation(s)
- Jan Henkel
- Institute of Health & Biomedical Innovation, Queensland University of Technology , Brisbane, Queensland, Australia
| | - Maria A Woodruff
- Institute of Health & Biomedical Innovation, Queensland University of Technology , Brisbane, Queensland, Australia
| | - Devakara R Epari
- Institute of Health & Biomedical Innovation, Queensland University of Technology , Brisbane, Queensland, Australia
| | - Roland Steck
- Institute of Health & Biomedical Innovation, Queensland University of Technology , Brisbane, Queensland, Australia
| | - Vaida Glatt
- Institute of Health & Biomedical Innovation, Queensland University of Technology , Brisbane, Queensland, Australia
| | - Ian C Dickinson
- Orthopaedic Oncology Service, Princess Alexandra Hospital , Brisbane, Australia
| | - Peter F M Choong
- Department of Surgery, University of Melbourne, St. Vincent's Hospital , Melbourne, Australia ; Department of Orthopaedics, St. Vincent's Hospital , Melbourne, Australia ; Bone and Soft Tissue Sarcoma Service, Peter MacCallum Cancer Centre , Melbourne, Australia
| | - Michael A Schuetz
- Institute of Health & Biomedical Innovation, Queensland University of Technology , Brisbane, Queensland, Australia ; Orthopaedic and Trauma Services, Princess Alexandra Hospital , Brisbane, Australia
| | - Dietmar W Hutmacher
- Orthopaedic Oncology Service, Princess Alexandra Hospital , Brisbane, Australia ; George W Woodruff School of Mechanical Engineering, Georgia Institute of Technology , Atlanta, GA, USA
| |
Collapse
|
13
|
Kim HN, Jiao A, Hwang NS, Kim MS, Kang DH, Kim DH, Suh KY. Nanotopography-guided tissue engineering and regenerative medicine. Adv Drug Deliv Rev 2013; 65:536-58. [PMID: 22921841 PMCID: PMC5444877 DOI: 10.1016/j.addr.2012.07.014] [Citation(s) in RCA: 267] [Impact Index Per Article: 22.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2012] [Revised: 07/19/2012] [Accepted: 07/23/2012] [Indexed: 12/14/2022]
Abstract
Human tissues are intricate ensembles of multiple cell types embedded in complex and well-defined structures of the extracellular matrix (ECM). The organization of ECM is frequently hierarchical from nano to macro, with many proteins forming large scale structures with feature sizes up to several hundred microns. Inspired from these natural designs of ECM, nanotopography-guided approaches have been increasingly investigated for the last several decades. Results demonstrate that the nanotopography itself can activate tissue-specific function in vitro as well as promote tissue regeneration in vivo upon transplantation. In this review, we provide an extensive analysis of recent efforts to mimic functional nanostructures in vitro for improved tissue engineering and regeneration of injured and damaged tissues. We first characterize the role of various nanostructures in human tissues with respect to each tissue-specific function. Then, we describe various fabrication methods in terms of patterning principles and material characteristics. Finally, we summarize the applications of nanotopography to various tissues, which are classified into four types depending on their functions: protective, mechano-sensitive, electro-active, and shear stress-sensitive tissues. Some limitations and future challenges are briefly discussed at the end.
Collapse
Affiliation(s)
- Hong Nam Kim
- Division of WCU Multiscale Mechanical Design, School of Mechanical and Aerospace Engineering, Seoul National University, Seoul 151-742, Republic of Korea
| | - Alex Jiao
- Department of Bioengineering, University of Washington, Seattle, WA 98195, USA
| | - Nathaniel S. Hwang
- School of Chemical and Biological Engineering, Institute for Chemical Processing, Seoul National University, Seoul 151-742, Republic of Korea
| | - Min Sung Kim
- Division of WCU Multiscale Mechanical Design, School of Mechanical and Aerospace Engineering, Seoul National University, Seoul 151-742, Republic of Korea
| | - Do Hyun Kang
- Division of WCU Multiscale Mechanical Design, School of Mechanical and Aerospace Engineering, Seoul National University, Seoul 151-742, Republic of Korea
| | - Deok-Ho Kim
- Department of Bioengineering, University of Washington, Seattle, WA 98195, USA
- Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98109, USA
| | - Kahp-Yang Suh
- Division of WCU Multiscale Mechanical Design, School of Mechanical and Aerospace Engineering, Seoul National University, Seoul 151-742, Republic of Korea
- Institute of Biological Engineering, Seoul National University, Seoul 151-742, Republic of Korea
| |
Collapse
|
14
|
Horch RE, Popescu LM, Polykandriotis E. History of Regenerative Medicine. Regen Med 2013. [DOI: 10.1007/978-94-007-5690-8_1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
15
|
Abstract
Stock market volatility in the cell therapy industry has greatly hindered the investment necessary to fund translational therapies. Here, we review the volatility of leading companies and suggest that a distinct industry is maturing to a point at which the volatility should subside, providing a more attractive environment for future growth.
Collapse
|
16
|
Hutmacher DW, Duda G, Guldberg RE. Endogenous musculoskeletal tissue regeneration. Cell Tissue Res 2012; 347:485-8. [DOI: 10.1007/s00441-012-1357-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2012] [Accepted: 01/31/2012] [Indexed: 01/04/2023]
|
17
|
Promissory futures and possible pasts: The dynamics of contemporary expectations in regenerative medicine. BIOSOCIETIES 2012. [DOI: 10.1057/biosoc.2011.24] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|
18
|
The Medialization of Regenerative Medicine: Frames and Metaphors in UK News Stories. SOCIOLOGY OF THE SCIENCES YEARBOOK 2012. [DOI: 10.1007/978-94-007-2085-5_5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
|
19
|
Mason C, Brindley DA, Culme-Seymour EJ, Davie NL. Cell therapy industry: billion dollar global business with unlimited potential. Regen Med 2011; 6:265-72. [DOI: 10.2217/rme.11.28] [Citation(s) in RCA: 86] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
20
|
Messenger MP, Tomlins PE. Regenerative medicine: a snapshot of the current regulatory environment and standards. ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2011; 23:H10-H17. [PMID: 21433095 DOI: 10.1002/adma.201100254] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Affiliation(s)
- Michael P Messenger
- Clinical and Biomedical Proteomics Group, Cancer Research UK Centre, Leeds Institute of Molecular Medicine, St James's University Hospital, UK.
| | | |
Collapse
|
21
|
Madeddu P. Stem cell therapy for cardiovascular regeneration: the beginning or the end of all hearts' hopes. Pharmacol Ther 2011; 129:1-2. [DOI: 10.1016/j.pharmthera.2010.09.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2010] [Accepted: 09/27/2010] [Indexed: 11/16/2022]
|
22
|
|
23
|
Smith D. Commercialization challenges associated with induced pluripotent stem cell-based products. Regen Med 2010; 5:593-603. [PMID: 20632862 DOI: 10.2217/rme.10.50] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
Induced pluripotent stem (iPS) cells have generated excitement in the regenerative medicine industry. Products derived from iPS cells could be used in a range of drug discovery and development processes. These nontherapeutic products will continue to be launched over the next 5 years, and provide income and knowledge to drive the therapeutic use of iPS cells forward. While the commercial opportunity for iPS cell-based therapies is potentially large, the looming technical and scientific hurdles must be overcome and, thus, the launch of a therapy based on iPS cells is unlikely to occur until the 2020s. While the launch of a therapeutic is many years away, the business models for commercialization should be well understood and proven based on experience with other non-iPS cell-based therapies (both autologous and allogeneic) that will already be on the market.
Collapse
Affiliation(s)
- Devyn Smith
- Strategic Management Group, Pfizer Global R&D, 50 Pequot Avenue, MS6025-C4171, New London, CT 06320, USA.
| |
Collapse
|
24
|
Affiliation(s)
- Chris Mason
- Advanced Centre for Biochemical Engineering, University College London, Roberts Building, Torrington Place, London, WC1E 7JE, UK
| | - Elisa Manzotti
- Future Medicine Ltd, Unitec House, 2 Albert Place, Finchley Central, London, N3 1QB, UK
| |
Collapse
|
25
|
Brindley D, Davie N. Regenerative medicine through a crisis: social perception and the financial reality. Rejuvenation Res 2010; 12:455-61. [PMID: 20041739 DOI: 10.1089/rej.2009.0981] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The aim of this perspective piece is to highlight how the "social perception" and "financial reality" of regenerative medicine may act to hinder its evolution into the principal health-care option for the future. We also consider the role of the consumer and the need for increased public awareness. Furthermore, we consider the effects of the changing social attitudes toward the field, as well as taking into account the influence of current and future political thinking. From a financial viewpoint, we analyze the compatibility of the current venture capital model with regenerative medicine start-ups and explore approaches to ensure sufficient funding and support throughout all stages of product development, for example, the modularization of funding.
Collapse
Affiliation(s)
- David Brindley
- Department of Biochemical Engineering University College London, Torrington Place, London, WC1E 7JE, United Kingdom
| | | |
Collapse
|
26
|
Duca M, Dozza B, Lucarelli E, Santi S, Di Giorgio A, Barbarella G. Fluorescent labeling of human mesenchymal stem cells by thiophene fluorophores conjugated to a lipophilic carrier. Chem Commun (Camb) 2010; 46:7948-50. [DOI: 10.1039/c0cc01918f] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|
27
|
Abstract
This report presents the recommendations to the ISSCR leadership from the industry panel session at the 2009 annual conference. The seven recommendations address core issues essential for the promotion of stem cell and regenerative medicine translation and commercialization.
Collapse
Affiliation(s)
- Chris Mason
- Advanced Centre for Biochemical Engineering, University College London, London, UK.
| |
Collapse
|
28
|
Plagnol AC, Rowley E, Martin P, Livesey F. Industry perceptions of barriers to commercialization of regenerative medicine products in the UK. Regen Med 2009; 4:549-59. [PMID: 19580404 DOI: 10.2217/rme.09.21] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
AIMS Regenerative medicine is an emerging field with the potential to provide widespread improvement in healthcare and patient wellbeing via the delivery of therapies that can restore, regenerate or repair damaged tissue. As an industry, it could significantly contribute to economic growth if products are successfully commercialized. However, to date, relatively few products have reached the market owing to a variety of barriers, including a lack of funding and regulatory hurdles. The present study analyzes industry perceptions of the barriers to commercialization that currently impede the success of the regenerative medicine industry in the UK. MATERIALS & METHODS The analysis is based on 20 interviews with leading industrialists in the field. RESULTS The study revealed that scientific research in regenerative medicine is thriving in the UK. Unfortunately, lack of access to capital, regulatory hurdles, lack of clinical evidence leading to problems with reimbursement, as well as the culture of the NHS do not provide a good environment for the commercialization of regenerative medicine products. CONCLUSION Policy interventions, including increased translational government funding, a change in NHS and NICE organization and policies, and regulatory clarity, would likely improve the general outcomes for the regenerative medicine industry in the UK.
Collapse
Affiliation(s)
- Anke C Plagnol
- Faculty of Politics, Psychology, Sociology & International Studies, University of Cambridge, Cambridge, CB2 3RQ, UK
| | | | | | | |
Collapse
|
29
|
Affiliation(s)
- Chris Mason
- Advanced Centre for Biochemical Engineering, University College London, Roberts Building, Torrington Place, London, WC1E 7JE, UK
| | - Elisa Manzotti
- Future Medicine Ltd, Unitec House, 2 Albert Place, Finchley Central, London, N3 1QB, UK
| |
Collapse
|
30
|
Mason C, Manzotti E. Induced pluripotent stem cells: an emerging technology platform and the Gartner hype cycle. Regen Med 2009; 4:329-31. [PMID: 19438302 DOI: 10.2217/rme.09.20] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
|
31
|
Schmelzeisen R, Sauerbier S. Br J Oral Maxillofac Surg 2009; 47:426-427. [DOI: 10.1016/j.bjoms.2008.10.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
32
|
Automated, serum-free production of CTX0E03: a therapeutic clinical grade human neural stem cell line. Biotechnol Lett 2009; 31:1167-72. [DOI: 10.1007/s10529-009-9989-1] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2009] [Revised: 03/16/2009] [Accepted: 03/17/2009] [Indexed: 10/21/2022]
|
33
|
Mironov V, Visconti RP, Kasyanov V, Forgacs G, Drake CJ, Markwald RR. Organ printing: tissue spheroids as building blocks. Biomaterials 2009; 30:2164-74. [PMID: 19176247 DOI: 10.1016/j.biomaterials.2008.12.084] [Citation(s) in RCA: 753] [Impact Index Per Article: 47.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2008] [Accepted: 12/31/2008] [Indexed: 12/13/2022]
Abstract
Organ printing can be defined as layer-by-layer additive robotic biofabrication of three-dimensional functional living macrotissues and organ constructs using tissue spheroids as building blocks. The microtissues and tissue spheroids are living materials with certain measurable, evolving and potentially controllable composition, material and biological properties. Closely placed tissue spheroids undergo tissue fusion - a process that represents a fundamental biological and biophysical principle of developmental biology-inspired directed tissue self-assembly. It is possible to engineer small segments of an intraorgan branched vascular tree by using solid and lumenized vascular tissue spheroids. Organ printing could dramatically enhance and transform the field of tissue engineering by enabling large-scale industrial robotic biofabrication of living human organ constructs with "built-in" perfusable intraorgan branched vascular tree. Thus, organ printing is a new emerging enabling technology paradigm which represents a developmental biology-inspired alternative to classic biodegradable solid scaffold-based approaches in tissue engineering.
Collapse
Affiliation(s)
- Vladimir Mironov
- Bioprinting Research Center, Cardiovascular Developmental Biology Center, Department of Cell Biology and Anatomy, Medical University of South Carolina, Charleston, SC 29425, USA.
| | | | | | | | | | | |
Collapse
|
34
|
Lysaght MJ, Jaklenec A, Deweerd E. Great Expectations: Private Sector Activity in Tissue Engineering, Regenerative Medicine, and Stem Cell Therapeutics. Tissue Eng Part A 2008; 14:305-15. [DOI: 10.1089/tea.2007.0267] [Citation(s) in RCA: 111] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Affiliation(s)
- Michael J. Lysaght
- Center for Biomedical Engineering, Brown University, Providence, Rhode Island
| | - Ana Jaklenec
- Center for Biomedical Engineering, Brown University, Providence, Rhode Island
- Current address: Department of Chemical Engineering, MIT, Cambridge, Massachusetts
| | - Elizabeth Deweerd
- Center for Biomedical Engineering, Brown University, Providence, Rhode Island
- Current address: Novartis Institutes for Biomedical Research, Cambridge, Massachusetts
| |
Collapse
|
35
|
Emmrich F. Abstracts of the 3rd World Congress on Regenerative Medicine, October 18-20, 2007, Leipzig, Germany. Regen Med 2007; 2:485-740. [PMID: 17941763 DOI: 10.2217/17460751.2.5.485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Affiliation(s)
- Frank Emmrich
- Congress President Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany
| |
Collapse
|
36
|
|